Status: Recruiting
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of BEBT-209 in combination with fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer.
Participants needed: 330
Trial details
Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: BeBetter Med IncUpdated: May 31, 2025Locations: 1
Eligibility criteria
Women aged 18 years or older who are postmenopausal or premenopausal/perimenopau... [+9]
The patient has provided written informed consent and is willing and able to com... [+16]